 |
인쇄하기
취소
|
Green Cross and OctoPlus signed joint development of new drug for mid-ear infection.
Green Cross signed an agreement with OctoPlus NV, a Netherlands company, on Nov. 22 for an exclusive distribution in Korea and joint development of OP-145, a drug for the treatment of chronic middle ear infection (otitis media).
OP-145 is an ear drop directly applicable to ears for the treatment of chronic mid-ear infections, which was newly developed by the research team of the Medical Cen...
OP-145 is an ear drop directly applicable to ears for the treatment of chronic mid-ear infections, which was newly developed by the research team of the Medical Cen...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.